Jacobs Appointed as EPCM Contractor for New Gene Therapy Manufacturing Facility
January 04 2018 - 7:45AM
Business Wire
Jacobs Engineering Group Inc. (NYSE:JEC) has received an
engineering, procurement and construction management (EPCM)
contract from Pfizer Inc. for a new gene therapy manufacturing
facility located at the company’s manufacturing site in Sanford,
North Carolina. Under the terms of the contract, Jacobs will
perform all required services to design, build and qualify the
multi-product facility, which will manufacture gene therapy
products upon completion. In addition to EPCM, Jacobs will provide
design, expediting and commissioning services for the project.
Gene therapy is an emerging area of medical research focused on
highly specialized, one-time, transformative treatments addressing
the root cause of diseases caused by genetic mutation.
“As a leader in gene therapy EPCM projects, Jacobs delivers
end-to-end solutions in support of gene therapy research and
advancement,” said Jacobs Life Sciences, Consumer Goods and
Manufacturing Senior Vice President and General Manager Ken
Gilmartin. “Working on this project, we envision a day in the
future when these potentially transformative gene therapies become
available to treat medical conditions to help people enjoy
healthier lives.”
Jacobs leads the global professional services sector delivering
solutions for a more connected, sustainable world. With $15 billion
in combined revenue and a talent force more than 74,000 strong,
Jacobs provides a full spectrum of services including scientific,
technical, professional and construction- and program-management
for business, industrial, commercial, government and infrastructure
sectors. For more information, visit www.jacobs.com.
Statements made in this release that are not based on historical
fact are forward-looking statements. We base these forward-looking
statements on management’s current estimates and expectations as
well as currently available competitive, financial and economic
data. Forward-looking statements, however, are inherently
uncertain. There are a variety of factors that could cause business
results to differ materially from our forward-looking statements.
For a description of some of the factors which may occur that could
cause actual results to differ from our forward-looking statements
please refer to our Form 10-K for the year ended September 29,
2017, and in particular the discussions contained under Items 1 -
Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 -
Management's Discussion and Analysis of Financial Condition and
Results of Operations. We do not undertake to update any
forward-looking statements made herein.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180104005133/en/
Jacobs Engineering Group Inc.Kerrie Sparks214.583.8433
Jacobs Engineering (NYSE:JEC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jacobs Engineering (NYSE:JEC)
Historical Stock Chart
From Jul 2023 to Jul 2024